Dataset Information

Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations.

ABSTRACT: Despite the existence of available therapies, the Hepatitis B virus infection continues to be one of the most serious threats to human health, especially in developing countries such as China and India. To shed light on the improvement of current therapies and development of novel anti-HBV drugs, we thoroughly investigated 212 US patents of anti-HBV drugs and analyzed the technology flow in research and development of anti-HBV drugs based on data from IMS LifeCycle databases. Moreover, utilizing the patent citation method, which is an effective indicator of technology flow, we constructed patent citation network models and performed network analysis in order to reveal the features of different technology clusters. As a result, we identified the stagnant status of anti-HBV drug development and pointed the way for development of domestic pharmaceuticals in developing countries. We also discussed about therapeutic vaccines as the potential next generation therapy for HBV infection. Lastly, we depicted the cooperation between entities and found that novel forms of cooperation added diversity to the conventional form of cooperation within the pharmaceutical industry. In summary, our study provides inspiring insights for investors, policy makers, researchers, and other readers interested in anti-HBV drug development.

SUBMITTER: Huang C

PROVIDER: S-EPMC5058496 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations.

Huang Chuoji C Lin Hui Heng HH Wan Jian-Bo JB He Chengwei C Hu Yuanjia Y

PloS one 20161011 10

Despite the existence of available therapies, the Hepatitis B virus infection continues to be one of the most serious threats to human health, especially in developing countries such as China and India. To shed light on the improvement of current therapies and development of novel anti-HBV drugs, we thoroughly investigated 212 US patents of anti-HBV drugs and analyzed the technology flow in research and development of anti-HBV drugs based on data from IMS LifeCycle databases. Moreover, utilizing ...[more]

PMID: 27727319

Similar Datasets

Project description:Research in computer systems often involves the engineering, implementation, and measurement of complex systems software and data. The availability of these artifacts is critical to the reproducibility and replicability of the research results, because system software often embodies numerous implicit assumptions and parameters that are not fully documented in the research article itself. Artifact availability has also been previously associated with higher paper impact, as measured by citations counts. And yet, the sharing of research artifacts is still not as common as warranted by its importance. The primary goal of this study is to provide an exploratory statistical analysis of the artifact-sharing rates and associated factors in the research field of computer systems. To this end, we explore a cross-sectional dataset of papers from 56 contemporaneous systems conferences. In addition to extensive data on the conferences, papers, and authors, this analyze dataset includes data on the release, ongoing availability, badging, and locations of research artifacts. We combine this manually curated dataset with citation counts to evaluate the relationships between different artifact properties and citation metrics. Additionally, we revisit previous observations from other fields on the relationships between artifact properties and various other characteristics of papers, authors, and venue and apply them to this field. The overall rate of artifact sharing we find in this dataset is approximately 30%, although it varies significantly with paper, author, and conference factors, and it is closer to 43% for conferences that actively evaluated artifact sharing. Approximately 20% of all shared artifacts are no longer accessible four years after publications, predominately when hosted on personal and academic websites. Our main finding is that papers with shared artifacts averaged approximately 75% more citations than papers with none. Even after controlling for numerous confounding covariates, the release of an artifact appears to increase the citations of a systems paper by some 34%. This metric is further boosted by the open availability of the paper's text.

Dataset Information

Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations.

Publications

Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets